Please check your internet connection and try again.
## Septran (co-trimoxazole)
### Overview
Septran is a combination antibiotic containing trimethoprim and sulfamethoxazole.
### Primary Indications
* Urinary tract infections (UTIs)
* Pneumocystis jirovecii pneumonia (PJP) prophylaxis and treatment
* Shigellosis
* Acute exacerbations of chronic bronchitis
### Adult Dosing
* **UTIs and Shigellosis:** 1 double-strength (DS) tablet (160 mg trimethoprim/800 mg sulfamethoxazole) every 12 hours for 3-14 days (UTI) or 5 days (shigellosis).
* **PJP Treatment:** 15 mg/kg/day (trimethoprim component) divided into 3-4 doses (e.g., 160 mg/800 mg every 6-8 hours) for 14-21 days.
* **PJP Prophylaxis:** 1 DS tablet (160 mg/800 mg) once daily, or 1 single-strength (80 mg/400 mg) tablet twice daily.
* **Acute exacerbations of chronic bronchitis:** 1 DS tablet (160 mg/800 mg) every 12 hours for 7-14 days.
### Pediatric Dosing
Dosing is based on the trimethoprim component, 15-20 mg/kg/day, divided into 2-4 doses. Actual dosing depends on the indication and severity.
* **UTIs and Shigellosis:** Typically 8-10 mg/kg/day (trimethoprim component) divided into two doses. For example, a child weighing 20 kg would receive 160-200 mg of trimethoprim per day, divided into two doses. Actual formulation and precise dosing should be confirmed with pediatric guidelines or local protocols.
* **PJP Treatment:** 15-20 mg/kg/day (trimethoprim component) divided into 3-4 doses.
* **PJP Prophylaxis:** 5-7.5 mg/kg/day (trimethoprim component) divided into two doses.
### Dose Adjustments
* **Renal Impairment:**
* CrCl > 30 mL/min: No adjustment needed.
* CrCl 15-30 mL/min: Half the usual dose.
* CrCl < 15 mL/min: Contraindicated.
### Contraindications
* Known hypersensitivity to trimethoprim or sulfamethoxazole.
* History of drug-induced immune thrombocytopenia with either component.
* Documented megaloblastic anemia due to folate deficiency.
* Infants less than 2 months of age (risk of kernicterus).
* Severe renal or hepatic insufficiency when pharmacokinetic monitoring is unavailable.
### Adverse Effects
Common: Rash, pruritus, nausea, vomiting, diarrhea, hyperkalemia.
Serious: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), bone marrow suppression (leukopenia, thrombocytopenia, megaloblastic anemia), hepatotoxicity, hyperkalemia, renal failure, photosensitivity.
### Key Drug Interactions
* **Warfarin:** Increased INR; monitor INR closely and adjust warfarin dose as needed.
* **ACE inhibitors and ARBs:** Increased risk of hyperkalemia.
* **Potassium supplements and potassium-sparing diuretics:** Increased risk of hyperkalemia.
* **Methotrexate:** Increased risk of bone marrow suppression; consider folate supplementation.
* **Cyclosporine:** Increased cyclosporine levels, potentially leading to nephrotoxicity.
* **Digoxin:** Increased digoxin levels, especially in elderly patients.
* **Potassium-dependent drugs (e.g., procainamide):** Increased risk of hyperkalemia.
### Monitoring
* Complete blood counts (CBC) with differential, especially during prolonged therapy or in patients with G6PD deficiency.
* Renal function (BUN, creatinine).
* Electrolytes, particularly potassium.
* Liver function tests.
* Therapeutic drug monitoring is not routinely recommended but may be considered in specific situations.
### Clinical Pearls
* Administer with adequate fluid intake to prevent crystalluria.
* Sulfa-containing products can cause severe and life-threatening hypersensitivity reactions. Discontinue immediately if rash or other signs of hypersensitivity occur.
* May interfere with urine glucose and bilirubin tests.
* Consider folate supplementation for patients on long-term therapy, those with G6PD deficiency, or those taking other folate antagonists.
**Disclaimer:** This information is intended for healthcare professionals. Always consult current prescribing information, institutional protocols, and patient-specific factors before making clinical decisions.
